RecruitingPhase 2NCT06161818
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
Studying Adenocarcinoma of the oesophagus and oesophagogastric junction
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Erasmus Medical Center
- Principal Investigator
- Bianca Mostert, MD, PhDErasmus Medical Centre
- Intervention
- FLOT-CROSS or CROSS-FLOT(drug)
- Enrollment
- 216 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (10)
- Catharina Ziekenhuis, Eindhoven, North Brabant, Netherlands
- Frisius medisch centrum, Leeuwarden, North Brabant, Netherlands
- Elisabeth Tweesteden Ziekenhuis, Tilburg, North Brabant, Netherlands
- Amsterdam UMC, Amsterdam, North Holland, Netherlands
- Erasmus Medical Centre, Rotterdam, South Holland, Netherlands
- Ziekenhuisgroep Twente, Almelo, Netherlands
- Antoni van Leeuwenhoek/Nederlands Kanker Instituut, Amsterdam, Netherlands
- Gelre ziekenhuis, Apeldoorn, Netherlands
- Leids Universitair Medisch Centrum, Leiden, Netherlands
- Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06161818 on ClinicalTrials.govOther trials for Adenocarcinoma of the oesophagus and oesophagogastric junction
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07432295Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)I-Mab Biopharma US Limited
- RECRUITINGPHASE1NCT07059299A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE1NCT07284186First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsPlexium, Inc.
- RECRUITINGPHASE2NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaAbbVie
- RECRUITINGPHASE2NCT05563766A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerVA Office of Research and Development
- RECRUITINGNANCT06649474Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1University Hospital, Clermont-Ferrand
- RECRUITINGPHASE1, PHASE2NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1, PHASE2NCT06324357Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadBoehringer Ingelheim
See all trials for Adenocarcinoma of the oesophagus and oesophagogastric junction →